Meniu
Asmeninė anketa Prisijungimas ir registracija
Atgal Pagrindinis » Autorių straipsniai » Medical Health » 2020 » Lapkričio » 5

Psychedelic treatment with psilocybin relieves major depression, study shows

Psychedelic treatment with psilocybin relieves major depression, study

In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.

A compound found in so-called magic mushrooms, psilocybin produces visual and auditory hallucinations and profound changes in consciousness over a few hours after ingestion. In 2016, Johns Hopkins Medicine researchers first reported that treatment with psilocybin under psychologically supported conditions significantly relieved existential anxiety and depression in people with a life-threatening cancer diagnosis.

Now, the findings from the new study, published Nov. 4 in JAMA Psychiatry, suggest that psilocybin may be effective in the much wider population of patients who suffer from major depression than previously appreciated.

"The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market," says Alan Davis, Ph.D., adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. "Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future 'gold-standard' placebo-controlled clinical trials." The published findings cover only a four-week follow-up in 24 participants, all of whom underwent two five-hour psilocybin sessions under the direction of the researchers.

"Because there are several types of major depressive disorders that may result in variation in how people respond to treatment, I was surprised that most of our study participants found the psilocybin treatment to be effective," says Roland Griffiths, Ph.D., the Oliver Lee McCabe III Professor in the Neuropsychopharmacology of Consciousness at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Center for Psychedelic and Consciousness Research. He says the major depression treated in the new study may have been different than the "reactive" form of depression in patients they studied in the 2016 cancer trial. Griffiths says his team was encouraged by public health officials to explore psilocybin's effects in the broader population of those with major depressive disorder because of the much larger potential public health impact.

For the new study, the researchers recruited 24 people with a long-term documented history of depression, most of whom experienced persisting symptoms for approximately two years before enrolling in the study. The average age of participants was 39; 16 were women; and 22 identified themselves as white, one person identified as Asian and one person identified as African American. Participants had to taper off any antidepressants prior to the study with the help of their personal physician to ensure safe exposure to this experimental treatment.

Thirteen participants received the psilocybin treatment immediately after recruitment and after preparation sessions, and 11 participants received the same preparation and treatment after an eight-week delay.

Treatment consisted of two psilocybin doses given by two clinical monitors who provided guidance and reassurance. The doses were given two weeks apart between August 2017 and April 2019 at the Johns Hopkins Bayview Medical Center Behavioral Biology Research Building. Each treatment session lasted approximately five hours, with the participant lying on a couch wearing eyeshades and headphones that played music, in the presence of the monitors.

All participants were given the GRID-Hamilton Depression Rating Scale—a standard depression assessment tool—upon enrollment, and at one and four weeks following completion of their treatment. On the scale, a score of 24 or more indicates severe depression, 17-23 moderate depression, 8-16 mild depression and 7 or less no depression. At enrollment, participants had an average depression scale rating of 23, but one week and four weeks after treatment, they had an average depression scale score of 8. After treatment, most participants showed a substantial decrease in their symptoms, and almost half were in remission from depression at the follow-up. Participants in the delayed group didn't show decreases in their symptoms before receiving the psilocybin treatment.

For the entire group of 24 participants, 67% showed a more than 50% reduction in depression symptoms at the one-week follow-up and 71% at the four-week follow-up. Overall, four weeks post-treatment, 54% of participants were considered in remission—meaning they no longer qualified as being depressed.

"I believe this study to be a critically important proof of concept for the medical approval of psilocybin for treatment of depression, a condition I have personally struggled with for decades," says entrepreneur and philanthropist Tim Ferriss, who supported the funding campaign for this study. "How do we explain the incredible magnitude and durability of effects? Treatment research with moderate to high doses of psychedelics may uncover entirely new paradigms for understanding and improving mood and mind. This is a taste of things to come from Johns Hopkins."

The researchers say they will follow the participants for a year after the study to see how long the antidepressant effects of the psilocybin treatment last, and will report their findings in a later publication.

Griffiths, whose research with psilocybin, begun in the early 2000s, was initially viewed by some with skepticism and concern, says he is gratified by Johns Hopkins' support and heartened by the dozens of startups and research labs that have followed suit with their own research. He says numerous companies are now actively working to develop marketable forms of psilocybin and related psychedelic substances.

According to the National Institute of Mental Health, more than 17 million people in the U.S. and 300 million people worldwide have experienced major depression.

Pasaulio naujienas kitaip... skaitykite Paranormal Telegram, FB ir X(twitter) kanale

...kadangi jau perskaitėte šį straipsnį iki pabaigos, prašome Jus prisidėti prie šio darbo. Skaitykite „Paranormal.lt“ ir toliau, skirdami kad ir nedidelę paramos sumą. Paremti galite Paypal arba SMS. Kaip tai padaryti? Iš anksto dėkojame už paramą! Nepamirškite pasidalinti patikusiais tekstais su savo draugais ir pažįstamais.

Turite savo nuomone, tapk autoriumi, prisijunk ir rašykite bloge. Dalinkitės receptais, sveikatos patarimais, nutikimais, susidūrėte su nekasdieniškais reiškiniais. Galite išversti iš užsienio kalbos, talpinkite su nuoroda. Laukiame Jūsų straipsnių, naujienų, apžvalgų ar istorijų!

Niekas neišdrįso palikti komentaro.
Būkite pirmi, kurie pasidalins savo nuomonėmis su kitais.
avatar

Nemokami skelbimai

TAIP PAT SKAITYKITE:
02.11.2024 laikas 21:09 Receptai Skanūs dietiniai duonos receptai: sveikai ir skaniai
Daugelis žmonių mano, kad duona gali būti kliūtis siekiant sveikos gyvensenos ir figūros, tačiau tai neturi būti tiesa! Šiandien pristatome tris skanius dietinės duonos receptus, kuriuos galite lengvai pagaminti namuose. Su šiais ...

Skaityti daugiau

01.11.2024 laikas 15:51 Receptai Traškūs Cukinijų Blyneliai: Sveikas Ir Skanus Pusryčių Pasirinkimas

Cukinijų blynai – tai ne tik skanus patiekalas, bet ir puikus būdas išsaugoti šviežių daržovių naudingas medžiagas. Šiame recepte cukinijos pjaustomos mažais gabaliukais, kad jų skonis ir tekstūra būtų akcentuoti. Pamiršk...

Skaityti daugiau

31.10.2024 laikas 20:42 Receptai Sultingi marinuoti šašlykai: Patikimas receptas su svogūnais
Marinuoti šašlykai yra klasikinis patiekalas, kuris puikiai tinka tiek šventėms, tiek kasdienei vakarienei. Tačiau, kad šašlykai būtų sultingi ir aromatingi, svarbu žinoti, kaip juos tinkamai paruošti. Šiame straipsnyje pasidalins...

Skaityti daugiau

04.11.2024 laikas 09:16 Kodėl nevertiname artimųjų, kai jie yra šalia?
Šiandieniniame pasaulyje, kai technologijos leidžia bendrauti akimirksniu, vis daugiau žmonių jaučiasi vieniši net būdami šalia mylimų žmonių. Kodėl mes nepasinaudojame proga vertinti ir būti kartu? Ar tai patogumo, užimtumo ar nepasitikėjimo rezulta...

Skaityti daugiau

03.11.2024 laikas 19:47 FTB konfiskuoja Diddy ‘šantažo juostas’ su Kamala Harris ir J.Lo

Šiandienos pramogų ir politikos susikirtimas atskleidžia tamsias paslaptis, kurios gali pakeisti ne tik elitą, bet ir visą politinį kraštovaizdį. Neseniai Diddy skandalai palietė ne tik jo asmeninį gyvenimą, bet ir įžymybių, tokių kaip Jennifer Lo...

Skaityti daugiau

03.11.2024 laikas 16:11 Kodėl kelnės buvo uždraustos senovės Romoje ir kaip jos tapo privalomu garderobo elementu?
Romos imperija, turinti didelę įtaką pasaulio kultūrai, išsiskiria ir savo drabužių tradicijomis. Kelnės, kurios anksčiau buvo laikomos barbarų simboliu, pamažu tapo neatsiejama vyriško garderobo dalimi. Šiame straipsnyje nagrinėsime, kaip ir kodėl š...

Skaityti daugiau

03.11.2024 laikas 13:35 Senovės garsai: ar Egipto piramidės galėjo paveikti sąmonę?

Egipto piramidės, šimtmečius stebinančios savo didybe ir tikslumu, slepia daugiau nei tik faraonų kapavietes. Naujausi moksliniai tyrimai atskleidžia intriguojančią galimybę, kad šie didingi statiniai buvo sukurti ne tik architektūros šedevrams, b...

Skaityti daugiau

03.11.2024 laikas 10:26 Trumpų šeimos imperija: nuo Frederiko iki Donaldo Trumpų

Trumpų šeima – tai garsi ir įtakinga dinastija, kurios šaknys siekia XIX a. pab. ir kurios istorija kupina neįtikėtinos verslo sėkmės, rizikų ir drąsių sprendimų. Frederiko Trumpo, Donaldo Trumpo senelio, gyvenimo kelias rodo ne tik verslumo...

Skaityti daugiau